MedTrace Logo

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

NCT05549505 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2025-08-29

Study results available
· View outcomes & findings →

Summary

This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.

Conditions

Interventions

DRUG

ARV-471

100 mg tablet

DRUG

Anastrozole

1 mg tablet

PROCEDURE

Surgical resection of breast tumor

Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)

Sponsors & Collaborators

  • Arvinas Inc.

    lead INDUSTRY

  • Pfizer

    collaborator INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2024-07-13
Completion
2024-07-25
FDA Drug
Yes

Countries

  • United States
  • Georgia
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05549505 on ClinicalTrials.gov